Conclusions
DISEASE
The study did not meet its primary endpoint. However, regorafenib was well tolerated and did not preclude subsequent treatments. Patients with good prognostic features (single metastatic site and lung-limited disease) reported clinical benefit with regorafenib.The exploratory metabolic analysis suggests that baseline [The identification of patients suitable for a less intensive treatment might guide further development of regorafenib in an earlier setting, prolonging the chemotherapy-free interval within the sequence of treatments for patients with 